The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
American journal of respiratory and critical care medicine
RATIONALE: Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for OSA. However, recent studies have demonstrated improvement in OSA with combined antimuscarinic and noradrenergic drugs.
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine in the treatment of OSA.
METHODS: Phase 2, randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (NCT05071612).
MEASUREMENTS AND MAIN RESULTS: Of 211 randomized patients, 181 were included in the pre-specified efficacy analyses. Sleep was assessed by two baseline and two treatment polysomnograms. Apnea-hypopnea index (AHI
CONCLUSIONS: AD109 showed clinically meaningful improvement in OSA, suggesting further development of the compound is warranted. Clinical trial registration available at www.
CLINICALTRIALS: gov, ID: NCT05071612. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, et al[ Sangal RB] The combination of aroxybutynin and atomoxetine in the treatment of obstructive sleep apnea (MARIPOSA): a randomized controlled trial. Am J Respir Crit Care Med. 2023 Oct 9. doi: 10.1164/rccm.202306-1036OC. Epub ahead of print. PMID: 37812772.